PRESS STATEMENT ON VOLUNTARY RECALL OF TENOFOVIR/LAMIVUDINE/DOLUTEGRAVIR (300/300/50 MG) – 25th November 2022 - Pharmacy and Poisons Board

PPB - Services

our services

Featured Services

PPB Information

Regional Offices

Guidance Documents

Recall and Market Withdrawal

Press Announcements

Frequently Asked Questions (FAQs)

our services

Products

Products regulated by PPB

Vaccines and Biologicals

Blood & Blood Products

Medical Devices and IVDs

Food Supplements

Herbal and Complementary Medicines

authorisation facilitation

Apply For

Exports and Imports Permit

Inspection and Compliance

Students – Exams and Internship

Training and Continuing Education

Clinical Trials Studies in Kenya

Marketing Authorisation / Product Registration

Premises License

Practice License

Medical Representatives

Product Advertisements and Promotions

Complaints, Feedback and Enquiry

Submit Complaint

Stakeholder Feedback

PPB News Press Statement

November 28, 2022 / Public Relations / 0 Comments

PRESS STATEMENT ON VOLUNTARY RECALL OF TENOFOVIR/LAMIVUDINE/DOLUTEGRAVIR (300/300/50 MG) – 25th November 2022

PRESS STATEMENT _TLD_25th NOVEMBER, 2022

Author

Public Relations

Leave a comment Cancel reply